- Home
- BGH vs HRTX Comparison
BGH vs HRTX Comparison
Compare BGH & HRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGH
- HRTX
- Stock Information
- Founded
- BGH 2012
- HRTX 1983
- Country
- BGH United States
- HRTX United States
- Employees
- BGH N/A
- HRTX N/A
- Industry
- BGH Investment Managers
- HRTX Biotechnology: Pharmaceutical Preparations
- Sector
- BGH Finance
- HRTX Health Care
- Exchange
- BGH Nasdaq
- HRTX Nasdaq
- Market Cap
- BGH 318.8M
- HRTX 276.1M
- IPO Year
- BGH N/A
- HRTX 1987
- Fundamental
- Price
- BGH $16.37
- HRTX $1.35
- Analyst Decision
- BGH
- HRTX Strong Buy
- Analyst Count
- BGH 0
- HRTX 2
- Target Price
- BGH N/A
- HRTX $4.50
- AVG Volume (30 Days)
- BGH 61.5K
- HRTX 2.6M
- Earning Date
- BGH 01-01-0001
- HRTX 08-08-2025
- Dividend Yield
- BGH 10.06%
- HRTX N/A
- EPS Growth
- BGH N/A
- HRTX N/A
- EPS
- BGH N/A
- HRTX N/A
- Revenue
- BGH N/A
- HRTX $149,694,000.00
- Revenue This Year
- BGH N/A
- HRTX $10.62
- Revenue Next Year
- BGH N/A
- HRTX $12.99
- P/E Ratio
- BGH N/A
- HRTX N/A
- Revenue Growth
- BGH N/A
- HRTX 9.78
- 52 Week Low
- BGH $11.92
- HRTX $1.04
- 52 Week High
- BGH $14.50
- HRTX $2.68
- Technical
- Relative Strength Index (RSI)
- BGH 63.33
- HRTX 36.48
- Support Level
- BGH $15.76
- HRTX $1.33
- Resistance Level
- BGH $16.43
- HRTX $1.43
- Average True Range (ATR)
- BGH 0.14
- HRTX 0.07
- MACD
- BGH -0.00
- HRTX 0.02
- Stochastic Oscillator
- BGH 91.04
- HRTX 45.45
About BGH Barings Global Short Duration High Yield Fund of Beneficial Interests
Barings Global Short Duration High Yield Fund is a diversified, closed-end management investment company. Its investment objective is to seek as high a level of current income as the Adviser determines is consistent with capital preservation.
About HRTX Heron Therapeutics Inc.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.